Q1 EPS Estimate for ORIC Pharmaceuticals Lowered by Analyst

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for shares of ORIC Pharmaceuticals in a research note issued to investors on Tuesday, February 18th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.52) for the quarter, down from their previous forecast of ($0.47). Wedbush currently has a “Outperform” rating and a $20.00 target price on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($2.16) per share. Wedbush also issued estimates for ORIC Pharmaceuticals’ Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.17) EPS, FY2026 earnings at ($2.00) EPS and FY2027 earnings at ($2.14) EPS.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.01.

A number of other analysts have also recently issued reports on the company. JPMorgan Chase & Co. lifted their price objective on ORIC Pharmaceuticals from $19.00 to $21.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Guggenheim reaffirmed a “buy” rating on shares of ORIC Pharmaceuticals in a report on Monday, February 10th. Wells Fargo & Company assumed coverage on ORIC Pharmaceuticals in a report on Thursday, October 31st. They issued an “overweight” rating and a $20.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a report on Tuesday, February 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Tuesday, January 14th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $18.71.

ORIC Pharmaceuticals Stock Down 5.9 %

Shares of ORIC Pharmaceuticals stock opened at $7.47 on Friday. The business has a fifty day simple moving average of $9.29 and a 200-day simple moving average of $9.50. ORIC Pharmaceuticals has a 12 month low of $6.33 and a 12 month high of $16.65.

Insider Buying and Selling

In related news, insider Pratik S. Multani sold 8,850 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total transaction of $73,278.00. Following the sale, the insider now owns 46,765 shares of the company’s stock, valued at approximately $387,214.20. This trade represents a 15.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jacob Chacko sold 24,660 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $204,184.80. Following the sale, the chief executive officer now directly owns 778,648 shares in the company, valued at $6,447,205.44. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,361 shares of company stock worth $350,749 in the last three months. Insiders own 5.55% of the company’s stock.

Hedge Funds Weigh In On ORIC Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ORIC. Creative Planning bought a new position in ORIC Pharmaceuticals during the 3rd quarter worth about $116,000. Hennion & Walsh Asset Management Inc. grew its holdings in shares of ORIC Pharmaceuticals by 34.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 137,962 shares of the company’s stock valued at $1,414,000 after acquiring an additional 35,528 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of ORIC Pharmaceuticals by 71.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company’s stock valued at $139,000 after acquiring an additional 5,646 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of ORIC Pharmaceuticals by 4.1% in the 3rd quarter. Victory Capital Management Inc. now owns 99,750 shares of the company’s stock valued at $1,022,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in ORIC Pharmaceuticals during the third quarter worth about $132,000. Institutional investors own 95.05% of the company’s stock.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.